{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Concord Drugs Ltd Valuation Shifts to Fair Amidst Elevated Price Multiples
Concord Drugs Ltd, a notable player in the Pharmaceuticals & Biotechnology sector, has experienced a significant shift in its valuation parameters, moving from an attractive to a fair rating. This change, coupled with a recent downgrade in its Mojo Grade from Hold to Sell, signals a critical juncture for investors assessing the stock’s price attractiveness amid evolving market dynamics.
Concord Drugs Ltd is Rated Sell
Concord Drugs Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 11 Dec 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 30 January 2026, providing investors with the latest insights into the company’s performance and outlook.
Concord Drugs Ltd is Rated Sell
Concord Drugs Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 11 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 19 January 2026, providing investors with the latest insights into the company’s performance and outlook.
Concord Drugs Ltd is Rated Sell
Concord Drugs Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 11 Dec 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 06 January 2026, providing investors with an up-to-date view of the company's fundamentals, valuation, financial trends, and technical outlook.
Concord Drugs Ltd is Rated Sell
Concord Drugs Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 11 Dec 2025. While the rating change occurred on that date, the analysis and financial metrics discussed here reflect the stock's current position as of 25 December 2025, providing investors with the latest insights into the company’s performance and outlook.
Concord Drugs Sees Shift in Market Assessment Amid Mixed Financial and Technical Signals
Concord Drugs, a key player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its market evaluation, reflecting a complex interplay of technical momentum, valuation metrics, financial trends, and broader market performance. This article analyses the factors influencing the recent changes in the company's assessment and what they imply for investors.
Concord Drugs Sees Revision in Market Evaluation Amidst Mixed Financial Signals
Concord Drugs, a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting a shift in analytical perspective. This adjustment follows a detailed review of the company’s recent financial and technical parameters, highlighting a complex picture of operational challenges and market momentum.
Is Concord Drugs overvalued or undervalued?
As of December 2, 2025, Concord Drugs is considered undervalued with a PE Ratio of 135.16 and a PEG Ratio of 0.63, outperforming peers like Sun Pharma and Divi's Lab, and achieving a year-to-date return of 106.29% compared to the Sensex's 8.96%.
How has been the historical performance of Concord Drugs?
Concord Drugs has experienced a declining trend in net sales and profits over the past four years, with net sales at 45.25 Cr in March 2025, down from 59.06 Cr in March 2022. Despite a slight increase in some metrics in 2025, overall financial performance remains challenging.
Concord Drugs Surges with Unprecedented Buying Interest, Eyes Multi-Day Upper Circuit
Concord Drugs has captured market attention with extraordinary buying momentum, registering a sharp price rise and entering an upper circuit scenario marked by an absence of sellers. This surge reflects robust investor enthusiasm and hints at a potential multi-day rally in the Pharmaceuticals & Biotechnology sector.
Concord Drugs Surges with Unprecedented Buying Interest, Poised for Multi-Day Upper Circuit
Concord Drugs has witnessed extraordinary buying momentum today, with the stock hitting an upper circuit and a complete absence of sellers in the queue. This remarkable demand surge signals the potential for a sustained multi-day circuit scenario, reflecting strong investor confidence in the Pharmaceuticals & Biotechnology sector.
Concord Drugs Faces Intense Selling Pressure Amid Consecutive Declines
Concord Drugs Ltd has encountered significant selling pressure in recent sessions, with the stock registering a sharp decline over the past four days and exhibiting a complete absence of buyers today. This sustained downward momentum highlights distress selling signals within the Pharmaceuticals & Biotechnology sector, contrasting sharply with broader market trends.
Why is Concord Drugs falling/rising?
On 21-Nov, Concord Drugs Ltd witnessed a notable decline in its share price, falling by 2.77% to close at ₹79.10. This drop comes after a three-day losing streak, reflecting a short-term correction despite the stock's impressive long-term performance.
How has been the historical performance of Concord Drugs?
Concord Drugs has experienced a declining trend in net sales and profits over the past four years, with net sales at 45.25 Cr in March 2025, down from 59.06 Cr in March 2022. While total assets increased to 65.14 Cr, profit after tax fell to 0.34 Cr in March 2025 from 1.59 Cr in March 2022.
Concord Drugs Q2 FY26: Profit Surge Masks Revenue Decline in Challenging Quarter
Concord Drugs Limited, a Hyderabad-based pharmaceutical manufacturer specialising in injectables and finished formulations, reported a net profit of ₹0.19 crores for Q2 FY26, marking a substantial 375.00% increase year-on-year from ₹0.04 crores in Q2 FY25. However, the profitability improvement came against a backdrop of declining revenues, with net sales falling 16.90% YoY to ₹10.28 crores. The company's stock, trading at ₹89.70 with a micro-cap market capitalisation of ₹82.00 crores, has surged 150.21% over the past year despite weak fundamental metrics including an anaemic ROE of 1.83% and elevated P/E ratio of 155x.
How has been the historical performance of Concord Drugs?
Concord Drugs has experienced a declining trend in net sales and profits over the past four years, with net sales at 45.25 Cr in March 2025, down from 59.06 Cr in March 2022. Despite a slight increase in operating profit, overall profitability has decreased significantly during this period.
Concord Drugs Ltd Faces Selling Pressure, Declines 5.00% Amid Ongoing Losses Over Two Days
Concord Drugs Ltd is experiencing notable selling pressure, with the stock declining over the past two days. Despite a strong monthly performance, recent trends suggest a shift in market sentiment. The stock remains above key moving averages, indicating a relatively strong long-term position amid current volatility.
How has been the historical performance of Concord Drugs?
Concord Drugs has experienced a declining trend in net sales and profits over the past four years, with net sales at 45.25 Cr in March 2025, down from 59.06 Cr in March 2022. Despite a slight increase in operating cash flow, profitability metrics such as profit before tax and profit after tax have also decreased significantly during this period.
Concord Drugs Hits New 52-Week High of Rs. 92.52, Surges 26%
Concord Drugs has achieved a new 52-week high of Rs. 92.52, reflecting strong performance with a 26.01% gain over the past four days. The microcap pharmaceutical company has outperformed its sector and delivered a remarkable 150.25% return over the past year, highlighting its growth in the industry.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
